Beauty Farm Medical and Health Industry Inc. announced that Mr. HU Tenghe and Mr. GENG Jiaqi have decided to step down from their current positions as non-executive Directors, and have tendered their resignations on August 18, 2025 with effect on the same day. The Board also announced that following Mr. Hu and Mr. Geng's resignations, the Board appointed Mr. GAO Jianming and Ms. YI Lin as non-executive Directors with effect from August 18, 2025. Set out below are the biographical details of Mr. Gao: Mr. Gao, aged 58, currently serves as chairman of Shanghai Homsun Equity Investment Fund Management Co.
Ltd. (), and also a shareholder of Naturade Health Technology Co. Ltd. () and holds a concurrent position as an independent non-executive director of Softcare Limited. Mr. Gao has over 30 years of experience in capital markets, investment management and corporate management.
In addition, Mr. Gao has worked at the finance department of Shanghai University of Finance and Economics (), and held several directorships in the listed companies: (i) Guangdong Keda Mechanical Electrical Co. Ltd. () (now known as Keda Industrial Group Co. Ltd. ()), (SH: 600499; SWX:KEDA); and (ii) Guangzhou Haozhi Industrial Co., LTD (), (SZ: 300503).
Mr. Gao obtained his bachelor's degree in economics in July 1985 and his master's degree in economics in January 1988 from the Shanghai University of Finance and Economics () in the PRC. Mr. Gao also obtained a doctor's degree in political economy from Fudan University () in the PRC in July 2002. Set out below are the biographical details of Ms. Yi: Ms. Yi, aged 43, currently serves as a partner at Beijing Defu Yue'an Investment Consultancy Limited () ("Defu Capital").
She has nearly 20 years of experience in investment and financing, investor relations, and financial management within China's healthcare industry, along with an extensive network of resources in the medical industry. DeFu Capital, where Ms. Yi is based, has invested in or acquired healthcare companies such as Jinxin Fertility (HKEX: 1951), Gaush Meditech (HKEX: 2407), Biokin Pharmaceutical (SH: 688506), Easton Biopharmaceuticals (SH: 688513), and Zylox-Tonbridge Medical (HKEX: 2190). Ms. Yi previously worked at PricewaterhouseCoopers Zhong Tian LLP (), where she was responsible for auditing and assurance services.
Ms. Yi obtained her bachelor's degree in literature from University of International Business and Economics () in the PRC in July 2006. She also obtained her Master of Business Administration (MBA) degree from Guanghua School of Management, Peking University () in the PRC in July 2016. The term of Mr. Gao and Ms. Yi's services as non-executive Directors are for three years commencing today and is subject to retirement and re-election at the annual general meetings of the Company pursuant to the articles of association of the Company.
Mr. Gao and Ms. Yi will not receive any remuneration in connection with their role as non-executive directors of the Company under the terms of this agreement. The two new Directors will bring fresh momentum to the Group's development with their extensive experience in capital markets and industry expertise. Following the resignation of Mr. Hu and the appointment of Mr. Gao, Mr. Gao has been appointed as a member of the remuneration committee of the Company in place of Mr. Hu, with effect from August 18, 2025.
